Table 1 Baseline characteristics of all acute myocardial infarction patients included in this study (n = 5658).
Demographics | |
Age in years, median (IQR) | 61.2 (54.0–69.6) |
Male, n (%) | 4587 (81.1) |
Race, n (%) | |
Chinese | 3532 (62.4) |
Malay | 1063 (18.8) |
Indian | 969 (17.1) |
Others | 94 (1.7) |
Risk factors | |
History of hypertension, n (%) | 3495 (61.8) |
History of diabetes, n (%) | 2126 (37.6) |
History of hyperlipidemia, n (%) | 3303 (58.4) |
History of MI/PCI/CABG, n (%) | 1431 (25.3) |
Smoking status, n (%) | |
Current | 2192 (38.9) |
Former | 998 (17.7) |
Never | 2440 (43.3) |
Killip class on admission, n (%) | |
I | 4737 (83.8) |
II | 299 (5.3) |
III | 353 (6.2) |
IV | 263 (4.7) |
CPR on admission, n (%) | 193 (3.4) |
Heart rate in BPM on admission, median (IQR) | 79 (67–93) |
Systolic blood pressure in mmHg on admission, median (IQR) | 135 (116–155) |
Abnormal cardiac enzymes within 72 h from MI onset, n (%) | 4743 (84.2) |
Serum creatinine in µmol on admission, median (IQR) | 90 (76–112) |
Haemoglobin in g/dL on admission, median (IQR) | 14.2 (12.7–15.3) |
Treatment during hospitalization | |
Aspirin, n (%) | 5469 (96.7) |
Beta blocker, n (%) | 4886 (86.4) |
ACEI/ARB, n (%) | 3980 (70.3) |
Lipid lowering drug, n (%) | 5486 (97.0) |
P2Y12 inhibitor, n (%) | 5557 (98.2) |
